I was working on the valuation of a biotech product in Dec 2012. I was almost done with all the cash flows and discount rates and I was about to calculate the net present value when one of my colleagues…
The casual answer to this question seems obvious, we would say “Yes”. Markets in these countries offer very favourable growth, usually double-digit, and their populations are several times larger than that of countries within the EU. Consider, for example, a…
La respuesta ”a bote pronto” a esta pregunta parece evidente, diríamos que Sí. Los mercados en estos paises ofrecen crecimientos muy importantes, normalmente de doble digito, siendo sus poblaciones varias veces superiores a la de paises de la EU, por…
La respuesta ”a bote pronto” a esta pregunta parece evidente, dir?amos que S?. Los mercados en estos pa?ses ofrecen crecimientos muy importantes, normalmente de doble d?gito, siendo sus poblaciones varias veces superiores a la de pa?ses de la EU, por…
Following the Wold Health Organisation?s approval of India?s vaccine regulatory system two weeks ago there has been much speculation over what the future holds for India?s Vaccine Industry. By achieving WHO approval the Industry has reached an important milestone that projects a bright…
In my last VIEW post, I discussed the difference between Cost of Capital of a project versus Cost of Capital of a company. In this post we understand whose discount rate we should use when valuing cash flows from out licensing. A…
Decision Tree Analysis (DTA) is one of the tools that is used to account for uncertainty and encapsulates the later decisions by the management. It is useful for analyzing sequential investment decisions at discrete points of time. In DTA, the…
With the recent rejection of Novartis? patent hitting the headlines India?s generic drug market is back in the news, this time Mumbai-based Glenmark Pharmaceuticals Ltd. is the target and Merck (MSD) is looking to sue over patent-infringement. Glenmark recently announced two anti-diabetic…
Hospira has announced yet another recall, this time related to copper particles found in sodium chloride injections that could potentially cause copper toxicity. Hospira, the largest US provider of sterile injectables has invested more than $375mn to upgrade its system, yet it…
April Fool?s day was anything but a joke for Novartis as India?s Supreme Court dismissed its application for patent protection of its Leukaemia and gastrointestinal cancer drug “Glivec” in India?s lucrative $13 billion-a-year drugs market. The ruling dealt a significant…